Videos

In part 7 of the discussion, experts reflect on access issues regarding foods recommended in the guidelines.

Part 6 of the discussion takes a closer look at added sugar recommendations from the guidelines and scenarios where individualization may be needed.

In part 5 of the discussion, the panel examines gaps within the pediatric sections of the updated dietary guidelines.

In part 4 of the discussion, experts review notable omissions and oversights in the guidelines, including fiber, whole grains, and plant-based foods.

In part 3 of this discussion, experts break down saturated fat recommendations and why visuals in the guidelines may cause confusion.

In part 2 of the discussion, experts discuss recommendations around protein intake, including controversy and misconceptions.

In the opening segment of this special report, a trio of experts discuss what's new in the 2025-2030 Dietary Guidelines.

Delay discounting links to residual depression symptoms but does not predict relapse after stopping antidepressant treatment in patients with remitted MDD.

In this Maui Derm Hawaii 2026 interview, key takeaways on contact dermatitis treatment strategies are highlighted by Liszewski.

Longitudinal data identify aromatic lactate–producing bifidobacteria and the metabolite 4-hydroxy-phenyllactate as key factors in early immune tolerance.

This interview at Maui Derm 2026 highlights notable takeaways regarding psoriasis treatment strategies and emerging therapies.

Despite usability concerns cited by the FDA, investigators say dibutepinephrine’s needle-free, portable design could still address gaps in real-world epinephrine use.

Anouti describes clinical uncertainties regarding signs of cholestatic liver disease, like jaundice, in patients with skin of color, and how this may impact transplant outcomes.

Catch up with major trial results, key FDA approvals, and more.

Greene discusses his recent study highlighting the limitations of quadruple therapy in reducing mortality and hospitalization rates among patients with HFrEF.

Catch up on disparities in IBD care, a potential new IBS drug, new insight on diet’s role in Crohn’s disease care, & more.

Catch up with major FDA decisions, key guidelines updates, and more.

Lee explains how understanding immune responses years before Crohn’s symptoms may open the door to earlier intervention and prevention strategies.

Freedman discusses a new analysis of the CARDIA study that indicates male patients’ greater risk of CHD at younger ages.

Although patients with remitted MDD showed greater impulsivity than controls, a study found no link between delay discounting and relapse risk after stopping antidepressants.

Lee explains what is known about the preclinical phase of Crohn’s disease before symptoms appear and describes his study on the role immune dysregulation plays.

Meta-analysis links longer preparation therapy and follow-up duration to depressive symptom change in psilocybin- and LSD-assisted treatment.

In this segment, Nancy Reau, MD, and Kimberly Brown, MD, discuss ongoing challenges with viral hepatitis elimination efforts and clinical shortcomings in screening.

Kianersi discusses how, although evening chronotype can be associated indirectly with increased CVD risk, this can be mediated via Life’s Essential 8 scores.

Milestone Pharmaceuticals’ novel, self-administered medication for paroxysmal supraventricular tachycardia has released alongside a patient support program.

Nancy Reau, MD, and Kimberly Brown, MD, discuss the challenges of accurately assessing and addressing alcohol use in patients with MASLD.

This interview with Stein Gold continues her discussion of new and emerging psoriasis therapies in 2026.

Noureddin recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.